Scholar Rock Holding has resubmitted its application for its spinal muscular atrophy treatment to the Food and Drug Administration. The biopharmaceutical company said that it has sent in a new ...

The Muscular Dystrophy Association (MDA) celebrates today’s announcement that the U.S. Food and Drug Administration (FDA) has approved a High Dose Regimen of SPINRAZA® (nusinersen) for the treatment ...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with ...

The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in ...

In the battle of the obesity bulge, glucagon-like peptide-1 receptor agonist medications — aka GLP-1s such as Wegovy and Zepbound — have changed the game for some people who've struggled to ...

Muscle atrophy is a prevalent condition in today's societies, but many of the roles that mitochondria play in the process remain unclear. In a recent study, researchers investigated how muscle atrophy ...

The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was ...

With the intensification of global population aging, muscle atrophy, characterized by the loss of muscle mass and function, has become an important health issue affecting the elderly. Researchers have ...

Lindsey Vonn is back on her feet after a wicked crash at the Olympics nearly cost her a leg. However, she suffered from ...